Recent landmark breakthroughs in research on anti-tumour immune response [33,34] have led to a shift of attention away from ARs on cancer cells to the metabolism of ADO and its role as an endogenous agonist of ARs on immune cells in the tumour niche [7,8,17,21,35,36]. The gene discussed is ADO; the disease is neoplasm.